Similar articles

• Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.

  Deprez-de Campeneere D, Baurain R, Trouet A. Deprez-de Campeneere D, et al. Cancer Treat Rep. 1979 May;63(5):861-7. Cancer Treat Rep. 1979. PMID: 455327
• Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

  Deprez-De Campeneere D, Baurain R, Huybrechts M, Trouet A. Deprez-De Campeneere D, et al. Cancer Chemother Pharmacol. 1979;2(1):25-30. doi: 10.1007/BF00253101. Cancer Chemother Pharmacol. 1979. PMID: 498415
• Tetrahydropyranyl derivatives of daunomycin and adriamycin.

  Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T. Umezawa H, et al. J Antibiot (Tokyo). 1979 Oct;32(10):1082-4. doi: 10.7164/antibiotics.32.1082. J Antibiot (Tokyo). 1979. PMID: 528373 No abstract available.
• Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.

  Seymour LW, Duncan R, Kopecková P, Kopecek J. Seymour LW, et al. Cancer Treat Rev. 1987 Dec;14(3-4):319-27. doi: 10.1016/0305-7372(87)90024-7. Cancer Treat Rev. 1987. PMID: 3326668 Review. No abstract available.
• Interaction with mitochondria of the anthracycline cytostatics adriamycin and daunomycin.

  Porumb H, Petrescu I. Porumb H, et al. Prog Biophys Mol Biol. 1986;48(2):103-25. doi: 10.1016/0079-6107(86)90002-7. Prog Biophys Mol Biol. 1986. PMID: 3029807 Review. No abstract available.